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Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune
disease characterized by the production of a variety of autoantibodies and by a
heterogeneity of clinical expression . In general, the autoantibody response in
SLE is directed toward two major classes of antigens: nuclear constituents and
cell surface molecules. There is evidence that surface-reactive antibodies may
influence disease expression by modulating lymphocyte subsets or by affecting
cell function (1). We have previously described DNA binding to the cell surface
of peripheral white blood cells in a manner consistent with a ligand-receptor
relationship (2). The binding ofX phage DNA to monocytes, Tcells, B cells, and
neutrophils, but not erythrocytes, was found to be a saturable phenomenon
inhibitablebyexcess cold DNA, but not RNA or mononucleotides. The apparent
Kd was 10-y M with ~10' molecules binding per cell. Electrophoresis of cell
membrane proteins followed by blotting onto nitrocellulose revealed a DNA-
binding protein migrating at a mol wt of ^-30,000. After internalization, the
receptor is reexpressed on the cell surface, a process that is inhibited by cyclo-
heximide. Binding of exogenous DNA to this receptor results in internalization
and subsequent degradation ofthe DNA to oligonucleotides. Other studies have
indicated that freshly isolated white blood cells have DNA on their cell surfaces
(3-5), and that this can act as the antigen for anti-DNA antibodies (6). We have
recently described (7) an apparent defect in DNA receptor function in patients
with SLE and kindred disorders. In this paper we amplify these observations and
describe experiments that indicate thatautoantibodies, found in SLE and similar
diseases, markedly affect the expression and function ofthe DNA receptor.
Materials and Methods
Patients.
￿
The sera used in this study were obtained from patients seen in the rheu-
matology clinics at Oregon Health Sciences University . Patients with SLE fulfilled four
or more of the 1982 criteria (8) for SLE. Patients with mixed connective tissue disease
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(MCTD)' had high titerantiribonucleoprotein antibodies, and a clinical overlap syndrome
as previously described (9). Patients with rheumatoid arthritis were all in the categories
of either definite or classical according to the 1958 criteria (10). Patients classified as
having Sjogren's syndrome all had the primary form of the disease with keratoconjuncti-
vitis sicca, a minor salivary gland biopsy score of 2 or greater, and at least one serological
abnormality in the form of a positive antinuclear antibody test or a positive rheumatoid
factor (11). No attempt was made to correlate the severity of disease expression with
timing of the serum specimen. The relatives of patients with SLE were either siblings,
parents, or adult children; none of them had ever been diagnosed as having SLE and
none had symptoms suggestive of SLE.
Reagents.
￿
a phage DNA was purchased from Bethesda Research Laboratories (Gaith-
ersburg, MD) and radiolabeled with sH by the method of nick translation (2). In cell-
binding experiments, the [sH]DNA was used as a tracer by mixing it in a constant
proportion to cold X phage DNA to give -8 x 104 cpm/,ug of total DNA. dNTPs,
cycloheximide, BSA, and transfer RNA were purchased from Sigma Chemical Co. (St.
Louis, MO); ['H]dTTP was purchased from Amersham Corp. (Arlington Heights, IL).
HBSS was purchased from Gibco Laboratories (Grand Island, NY). Cyanogen-activated
Sepharose 4B (CNBr-4B) and Ficoll-Paque were purchased from Pharmacia Fine Chemi-
cals (Piscataway, NJ). DNase 1 was purchased from Worthington Biochemical Corp.
(Freehold, NJ).
Cells.
￿
Human PBMC were used in all experiments. They were prepared from human
buffy coats (40-50 g) obtained from the local Red Cross within 3 h of collection. The
buffy coats were collected in acid citrate dextrose solution and centrifuged at 50 g to
remove contaminating platelets and diluted in HBSS before separation into PBMC and
erythrocytes/neutrophils by centrifugation over Ficoll-Paque. All cell preparations were
assessed for viability both after separation and at the conclusion of experiments by the
method of Trypan blue exclusion. The PBMC were washed once in HBSS and resus-
pended in HBSS containing 1 % BSA at a final concentration of 10' cells/ml. The cell
preparation contained >85% mononuclear cells and showed >93% viability at the initia-
tion of experiments with >78% viability at the termination of cell culture, which lasted
24 h.
Monoclonal Antibodies.
￿
Monoclonal antinuclear antibodies were produced by fusion of
NZB/NZW or MRL-lpr/lpr spleen cells (12). The characteristics and specificities of these
antibodies have been previously described in detail (12). Antibodies BWD-1 (IgG2a) and
BWD-2 (IgG2b) recognize both ssDNA and dsDNA. Antibody BWH-1 (IgG2a) recognizes
the histone H2A-H2B complex, but fails to bind to individual histones (i.e., H1, H2A,
H2B, H3, and H4). Antibody MH-2 (IgM) binds to individual histones H2A, H3, and
H4. mAbs for most experiments were prepared from supernatants ofthe cloned cell lines,
concentrated 10-fold to a concentration of ^-150 ug/ml. An irrelevant monoclonal IgG2a
antibody (RPC-5 ; Litton Bionetics, Inc., Charleston, SC) added at the same concentration
to supernatant of the nonsecreting parent myeloma line, was used as a control. In other
experiments, IgG mAbs were purified from ascites fluid by Sephadex G-200 gel filtration
(12). Ascites fluid from an animal injected with the nonsecreting parent myeloma served
as a control. Preparations of the anti-DNA or antihistone mAbs demonstrated no cross-
reactivity for histone or DNA, respectively, compared with irrelevant control monoclonals
(12).
Preparation ofHistonesfrom Chromatin.
￿
Chromatin was isolated from calf thymus (Pel-
Freez Biologicals, Rogers, AR) and histones free of DNA were then extracted with 0.4 M
NH2S04 (12). Purified anti-DNA mAbs demonstrated no reactivity in ELISA when these
histones were used as antigen and coated to plates at saturation (12). The histone
preparation showed no uptake ofethidium bromide when subjected to agarose gel analysis.
DNA Affinity Chromatography.
￿
DNA was coupled to cyanogen-activated Sepharose 4B
as previously described (6). Briefly, calf thymus DNA (Worthington Biochemical Corp.)
was dissolved in 10 mM KP04, pH 8.0 (75 m/25 ml buffer). The dissolved DNA was
boiled for 10 min and then cooled on ice, to render it predominantly single stranded.
'Abbreviation used in this paper:
￿
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CNBr-Sepharose 4B (Pharmacia Fine Chemicals) was washed five times with 0.001 M
HCI and then two times with the 10-mM KOP4 buffer, before incubation with the
dissolved DNA . After centrifugation, the OD266 of the supernatant dropped to back-
ground . Thereafter, it was washed one time with 1 M KCl and once with 0.1 M NaOH .
The remaining active groups on the CNBr-Sepharose were then blocked by incubation at
25 °C for 30 min with 0.2 M glycine, pH 8.0 . Final washes with 0.1 M acetate, 0.5 M
NaCl, pH 4.0, and 0.1 M NaHCO,, 0.5 M NaCl, pH 8.3, preceded storage of the DNA-
Sepharose in PBS containing 0.1% sodium azide . Sera were depleted of anti-DNA
antibodies by repeated passage over a column of the immobilized DNA . The efficacy of
removal was assessed by the measurement of anti-DNA antibodies by an ELISA using
ssDNA coated to microtiter wells . In some experiments, the glycine eluate (0.2M glycine,
pH 2.0) was used as a source of affinity-purified anti-DNA antibodies ; in other experi-
ments, anti-DNA antibodies were eluted by means of mononucleotides (see below) .
IgG and its F(ab)2 Fragment.
￿
Affinity-purified anti-DNA antibodies were isolated from
a patient with active SLE whose serum gave 96% DNA binding in a standard Farr assay .
The IgG fraction was prepared by DEAE cellulose (Whatman DE-32) ion-exchange
chromatography (13), and anti-DNA antibodies were isolated using the procedure de-
scribed by Manak and Voss (14) . Briefly, the IgG fraction was dialyzed against PBS
overnight at 4'C and then incubated for 18 h at 37'C with DNA-Sepharose . After three
washes with PBS, the anti-DNA antibodies were eluated by incubation with 0.025 M
mononucleotides (dAMP, dCMP, dGMP, and dTTP) in 0 .005 M PBS, pH 8.0 . Igs were
precipitated by the addition of ice-coldammonium sulfate to a final concentration of50% ;
the precipitate was redissolved in PBS and chromatographed over Sephacryl S-200 to
purify the IgG fraction and remove ammonium sulfate . F(ab) 2 fragments were prepared
by pepsin digestion and the F(ab)2 fragments were isolated by exclusion chromatography
using Sephadex G 150 . The F(ab)2 fraction was then passed over a column of protein A-
Sepharose (Pharmacia Fine Chemicals) to remove undigested IgG and Fc fragments . The
purity of the IgG and F(ab)2 fragments was verified by SDS-PAGE using nonreducing
conditions . The reactivity of the F(ab) 2 with DNA was assessed by incubating 10 jug of
'25I-labeled F(ab) 2 with 500 ug of salmon sperm DNA and applying the mixture to a
Sephacryl S300 column ; 97% of the radioactivity eluted with the DNA at the void volume .
F(ab) 2 prepared from IgG of a healthy control was not reactive with DNA under similar
conditions .
DNA Receptor Assay .
￿
Specific ['H]DNA binding to PBMC used modification of the
methodology previously described (2) . PBMC suspended in HBSS plus 0.5% BSA were
plated in V-bottomed 96-well trays at 2 x 106 cells/well . X phage [sH]DNA (400 ug in I
ml) was then incubated with the cells for 1 h at 4°C . After washing five times in 400 k]
of HBSS, the cells were disrupted with 1 N NaOH and the bound ['H]DNA was counted
using 5 ml of 3 A 70 scintillation cocktail (Research Products International Corp ., Mt .
Prospect, IL) . Nonspecific binding was assessed by measuring the binding of['H]DNA to
trypsinized cells (5 mg/ml, 30 min, 37'C) . In some experiments, the PBMCs were stripped
of their endogenous cell surface DNA by DNase (500 jug/ml, 37°C, 1 h) . The effects of
sera, Igs, F(ab)2 fragments, and mAbs were assessed as follows . PBMC (2 x 106 in HBSS
+ 0 .5% BSA) were incubated with 50 Eel of the specific humoral modulator, at concentra-
tions described in individual experiments, for 30 min at 37°C . After washing three times
with HBSS, the [6H]DNA binding assay was performed as described above .
Internalization Assay.
￿
The uptake of exogenously added DNA and subsequent degra-
dation to oligonucleotides (<12 bp) was assessed as previously described (2) . PBMC
(10'/ml) were kept in continuous suspension in HBSS at 37 °C . [ H]DNA was added to a
final concentration of 200 kg/ml at time 0 . Thereafter, timed aliquots of 100 tcl of
suspension (106 cells) were washed once with PBS, twice with 0.1 M acetic acid, and finally
once with PBS ; this procedure was previously shown to remove >92% of cell surface-
associated DNA from cells incubated at 4°C . To measure intracellular ['H]DNA, the cell
pellet was solubilized in 1 N NaOH and counted ; TCA (final concentration, 5%) was
added to a small aliquot diluted to 100 j1 with PBS + 5% BSA and the percentage of
precipitated counts was assessed as a measure of DNA degradation . In an otherwisem
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FIGURE 1 . Humoral Inhibition of DNA re-
ceptor binding of ['H]DNA. Serum (dilution
1 :5) was incubated with the PBMC from a
healthy volunteer at 37°C for 30 min; after
washing, the binding of ['HIDNA was meas-
ured. The mean ['H]DNA binding using the
sera from 29 healthy controls was arbitrarily
designated as 100%. The change in [H]DNA
binding induced by the patients sera is dis-
played as a percentage of the mean counts of
the normal controls. Where there is a discrete
clustering of points (normals, SLE, and
MCTD), the mean (horizontal line) and SEM
(hatched box) are shown.
identical experiment, 100 Ag/ml of affinity-purified anti-DNA F(ab)2 was incubated with
the PBMC for 30 min at 37°C, and after washing three times with PBSS, ['H]DNA was
added at time 0 and its interiorization and degradation were assessed as described.
Detection of Antireceptor Antibodies by Immunoblotting.
￿
Cell membranes from PBMC
were prepared as previously described (2). Briefly, 10' DNase-treated cells were homog-
enized in 10 mM phosphate (pH 7 .4), 0.005 M PMSF, 1 mM dithiothreitol, 10 mM EDTA
sodium azide, 10 Rcg/ml DNase, 1 MM MgCl2, and 30 mM NaCl. An ice-cooled cell
suspension was disrupted by 2-3 s bursts of a Polytron homogenizer (Brinkmann Instru-
ments Co., Westbury, NY) using a power setting of seven. The homogenate was layered
over 4% sucrose and centrifuged at 95,000 g for 1 h. The purified cell membranes were
collected at the buffer/sucrose interface and were aspirated and washed three times in
homogenization buffer. The membrane pellet was boiled for 2 min in a 0.06-M Tris-HC1
buffer (pH 6.8) containing 2% SDS. The samples were diluted to a protein concentration
of 50 ug/ml and mixed with 20% glycerol and 0.001% bromophenol blue before SDS-
PAGE (9% polyacrylamide in 3 .75 M Tris HCl buffer, 0.1% SDS, pH 8.8; stacking gel
3% polyacrylamide in 0.125 M Tris HCl buffer, 0.1% SDS, pH 6.8). The separated
proteins were electrophoretically transferred to nitrocellulose sheets (Bio-Rad Laborato-
ries, Richmond, CA) using a Trans Blot apparatus (Bio-Rad Laboratories). The nitrocel-
lulose sheet was cut into strips for further processing: (a) the position ofthe DNA receptor
protein was demonstrated using a probe of biotin-labeled DNA as previously described
(2, 15); (b) one strip was incubated with the IgG of an asymptomatic SLE relative (this
serum had been extensively adsorbed over DNA-Sepharose and was still found to induce
receptor dysfunction in DNAse-treated cells); and (c) in control experiments, strips were
incubated with normal human serum in one instance and preincubated with DNA (10
tg/ml) before incubation with the test serum in another experiment. Bands of fixed Igs
were visualized by means of a peroxidase-conjugated goat anti-human IgG developed
with diaminobenzidine tetrahydrochloride.
Results
Induction ofa DNA Receptor Defect by Humoral Factors.
￿
Normal human PBMC
were incubated at 37 *C for 30 min with sera (1 :5 dilution) obtained from normal
individuals or patients with SLE and related diseases, and then tested for their
ability to bind [3H]DNA (Fig. 1). Incubation of cells with normal sera did not
materially affect the binding of ['HIDNA when compared with untreated cells.
The mean ['HIDNA binding of cells incubated with 20 normal sera was arbi-
trarily assigned as 100% and the effect of patient's sera was compared with this
figure. All SLE sera tested inhibited DNA binding (mean ± SE, 77 ± 8%; range,854
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FIGURE 2 . Inhibitory effect of anti-DNA
F(ab)2 on [sH]DNAbinding; reversal by culture
requires active receptor regeneration . PBMC
from a healthy volunteer were incubated with
the F(ab)2 fraction of IgG from a normal con-
trol and with anti-DNA F(ab)2 from a patient
with SLE at a concentration of 660 ug/ml, at
37 °C for 30 min ; [sH]DNA bindingwas meas-
ured at (p) time 0 (i .e ., immediately after wash-
ing F(ab)2-treated cells) and at (®) 24 h after
theend ofthe incubation with F(ab)2 . Foreach
F(ab)2 incubation a similar experiment was per-
formed on PBMC that had been treated with
cycloheximide (") . The results shown are the
mean of three experiments, the bars represent
the SEM . The mean base-line binding at time
0, in the absence ofantibodies, was 3,200 cpm .
53-94% inhibition) . No overlap was observed between the values obtained with
normal sera andSLE sera . All sera obtained from patients with MCTD induced
marked inhibition of DNA binding (mean inhibition ± SE, 76 ± 12%; range,
36-84% inhibition) . Sera from some patients with rheumatoid arthritis and
primary Sjogren's syndrome showed inhibition similar to that seen in SLE, while
other sera demonstrated minimal or no inhibition . Particularly interesting is the
observation that the sera from many asymptomatic first degree relatives of
patients with SLE also caused a profound inhibition ofDNA binding .
Anti-DNA Antibodies in SLE Sera Induce the DNA Receptor Defect .
￿
We consid-
ered the possibility that anti-DNA antibodies in SLE sera might mediate the
DNA receptor defect, perhaps by interacting with DNA already bound to the
receptor on freshly isolated PBMC (6) . We correspondingly prepared affinity-
purified anti-DNA antibodies from SLE sera . To ensure that Fc-receptor binding
was not participating, F(ab)2 fragments of the affinity-purified Igs were prepared,
and their ability to affect DNA binding was compared with that of IgG F(ab)2
prepared from a pool ofnormal sera . These F(ab)2 preparations were incubated
with normal PBMC for 30 min at 37°C and the binding of [sH]DNA was studied
immediately after incubation with antibody or after 24 h of culture (Fig . 2) .
Affinity-purified anti-DNA F(ab)2 resulted in a profound reduction in [sH]DNA
binding when cells were tested immediately after washing (Fig . 2) . However, this
inhibition was abrogated if cells were incubated for an additional 24 h (without
antibody) after the initial exposure to the anti-DNA antibodies . It should be
noted that DNA binding is nearly doubled when freshly isolated PBMC are
incubated in culture for 24 h, whether or not PBMC had been preincubated
with normal F(ab)2 . When cells were incubated with cycloheximide for 15 min
and washed once before culture, no increase in DNA binding was observed over
a 24-h period, whether cells had been pretreated with normal F(ab)2, anti-DNA
F(ab)2, or without any antibodies .BENNETT ET AL.
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TABLE I
Induction ofDNA Receptor Dysfunction by mAbs
Freshly isolated PBMC (10'/ml) wereincubatedwith each mAbor serum(dilution
1:5) for 30 min at 37°C. Afterwashing, DNA receptor function was assessed by
measuring the binding of ['H]DNA. IgG2a refers to the Ig subclass of an
irrelevant mAb used as a control. Pretreatment of the PBMC with DNAase is
seen to abrogate thereceptor loss induced by anti-DNA andantihistone antibod-
ies. Each value represents the results triplicate experiment. Similar results were
obtained on repeating this experiment on four different occasions.
Monoclonal Anti-DNA and Antihistone Antibodies Induce a DNA Receptor De-
fect. To further determine whether anti-DNA antibodies mediated the DNA
receptor defect, we studied the effect of murine mAbs specific for DNA.
Monoclonal antihistone antibodies and irrelevant mAb ofthe same IgG subclasses
were used as controls.
As is shown in Table 1, the two anti-DNA mAbs markedly reduced the binding
of [sH]DNA to freshly isolated PBMC. To further determine whether these
antibodies were functioning via their DNA specificity, we also tested their ability
to inhibit DNA binding to cells pretreated with DNAase. Prior DNAase treat-
ment prevented the anti-DNA antibody-induced receptor defect (Table I). The
serum from a BALB/c mouse, the IgG2a control supernatant, and control ascites
fluid did not influence the expression of the DNA receptor. Somewhat surpris-
ingly, the two antihistone mAbs had a profoundly depressive effect on DNA
binding, which was quantitatively equal to that observed with the anti-DNA
mAbs (Table I). This inhibition by antihistone antibodies was also abrogated by
prior treatment of the cells with DNAase (Table I). These results confirmed the
involvement of DNA and anti-DNA antibodies in modulating a DNA-receptor
function, but also suggested an unexpected role for histone and antihistone
antibodies. Interestingly, the latter reactivity depended upon the presence of
cell-surface DNA.
Effect ofDNAase and Reconstitution with DNA and Histones on Antibody-mediated
Receptor Dysfunction. As demonstrated above, the exposure of PBMC to
DNAase 1 before incubation with either anti-DNA or antihistone antibodies,
abrogates the loss of the DNA-receptor. This result was expected in the case of
anti-DNA antibodies, but it remained unclear as to why the removal of cell-
surface DNA abrogates the effect of antihistone antibodies. In an attempt to
elucidate this observation, reconstitution experiments with histones and DNA
Antibody Source
[3H]DNA
binding (cpm,
mean ± SD)
Effect of
DNAse (cpm,
mean t SD)
Controls BALB/c serum 3,729 t 373 4,265 t 283
IgG2a supernatant 4,612 ± 475 4,732± 356
Controlascitesfluid 5,741 t 46 5,716f 205
Human lupusserum 291 t 58 4,683 f 156
Anti-DNA mAbs BWD-1 supernatant 902 f 67 4,326 t 216
BWD-2 supernatant 821 t 74 4,653 t 274
BWD-1-ascitic fluid 432 ± 81 3,991 ± 183
Antihistone mAbs BWH-1 supernatant 409 t 23 3,986 t 361
MH-2 supernatant 907 ± 101 4,743 ± 403
BWH-1 ascitic fluid 378 ± 83 3,867 t 312856
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FIGURE 3 .
￿
Anti-DNA and antihistone mAbs inhibit [ 3H]DNA binding ; abrogation by DNAse
treatment of cells and restoration by reconstitution with DNA and histones . .PBMCs from a
healthy volunteer were incubated with mouse serum (BALB/c) and mAbs to bothDNA (BWD-
1) and histone (BWH-1) at 37°C for 30 min . After washing, [H]DNA binding was measured .
In some instances cells were treated with DNAase before incubation with mAbs. A subset of
cells pretreated with DNAase was extensively washed and then incubated (RT, 30 min) with
DNA (100 ;&g/ml), or a mixture of total histones (15 ug/ml), or DNA followed by histones,
before measurement of [sH]DNA binding. The results shown are the mean offour experiments
done at different times, the bars represent the SEM . The mean base-line binding in the
absence of antibody was 6,480 cpm.
were performed on DNAase 1-treated PBMC (Fig . 3) . If DNAase-treated cells
were reconstituted with purified DNA, then subsequent treatment with an mAb
anti-DNA but not a monoclonal antihistone antibody inhibited DNA binding.
When purified histones were reacted with the DNA-reconstituted cells, both
anti-DNA and antihistone antibodies induced a defect inDNA receptor function .
When purified histones were reacted with DNAase-treated cells, without prior
reconstitution with DNA, a moderate inhibition (^-28%) of DNA binding was
observed after treatment with antihistone antibodies ; no inhibition was observed
after treatment with anti-DNA antibodies . These results suggest that antihistone
antibodies mediate DNA receptor dysfunction by binding to histones complexed
with DNA, which in turn is bound to theDNA receptor .
Kinetics of Receptor Dysfunction Induced by Autoantibodies.
￿
In all the previous
experiments cells had been routinely incubated with antibody for 30 min at 37'C
before assessing [3H]DNA binding . To determine the kinetics of the loss ofDNA
receptor function, freshly isolated PBMC were incubated with different antibody
preparations for increasing periods of time. The results of a representative
experiment are shown in Fig . 4 ; it is seen that compared with a normal F(ab)2
preparation, anti-DNA F(ab)2 and mAbs to DNA and histones cause an acceler-
ated loss of DNA-receptor function with a ty, of-3 min . A markedly attenuated
receptor loss (-12% at 5 min) occurred if cells were incubated with anti-DNA
antibodies at 4°C in the presence of 1 mM sodium azide (data not shown) .
Previous experiments have demonstrated the ty , of the DNA-receptor internali-a e
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￿
Kinetics of DNA
receptor loss after incubating
cells with anti-DNA and anti-
histone antibodies. Freshly iso-
lated normal PBMCs were in-
cubated with different anti-
body preparations for specific
time periods. At each time
point the cell suspension (100
,ul) was removed and immedi-
ately diluted with 1 ml of ice-
cold HBSS containing 0.1%
sodium azide. After a further
two washes with ice-cold
HBSS, the ['H]DNA binding
wasmeasured.The results are
expressed as a percentage of
['H]DNA binding in the ab-
sence of any antibodies
(22,000 cpm).
FIGURE 5.
￿
Restoration of DNA
receptor function during culture,
afterantibody-mediated receptor
loss. Normal PBMC were incu-
bated with affinity-purified anti-
DNA F(ab)2 at concentrations of
1 ug/ml and 100 jag/ml for 30
min at 37 °C. After extensive
washing the cells were placed in
culture and['H]DNAbindingwas
measured at timed intervals. The
mean base-line binding in theab-
senceofantibody was23,900 cpm
(hatched bar).
zation is -90 min after X phage DNA is bound to the cell surface (Bennett, R.
M ., and M . J. Merritt, unpublished observations).
We also studied the time course of the reexpression of DNA binding. PBMC
were incubated with increasing concentrations of antibody for 30 min, washed
extensively, placed back into culture, and then tested for DNA binding at various
times thereafter. Consistent with Fig. 2 above, marked reexpression occurred
between 4 and 18 h of culture with 1-100 ,ug/ml of antibody (Fig. 5). These
data should be compared with a reappearance time of 15 min if the surface
receptors are removed by trypsinization (data not shown).
Paralysis of Receptor Function.
￿
Previous experiments (2) have indicated that
binding of DNA to the DNA receptor allows for subsequent internalization and
degradation of DNA to oligonucleotides. We therefore studied whether incuba-
tion of PBMC with anti-DNA antibodies also prevented DNA internalization and
degradation. Under normal circumstances, exogenous DNA gains access to the
interior of the cells, as assessed by its resistance to acid washes, and it is degraded
to oligonucleotides as assessed by its inability to be precipitated by TCA (Fig. 6).858
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s2% FIGURE 6. Anti-DNA antibodies inhibit
the internalization and degradation of ex-
ogenous [sH]DNA. Normal PBMC were
kept in continuous suspension in HBSS
while incubating with [sH]DNA at 37°C. At
timed intervals the acid-resistant [3H]DNA
(internalized DNA) was measured, and an
aliquot of 1 N NaOH-solubilized cells was
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When affinity-purified anti-DNA F(ab)2 was incubated with the cells for 30 min
before the addition of 1251-DNA, the subsequent internalization and degradation
of the DNA was inhibited (Fig. 6). This effect of preincubation with anti-DNA
antibodies mimicked the previously observed action of cycloheximide (2), sug-
gesting that anti-DNA antibodies influence the regeneration and surface re-
population of DNA receptors.
Evidence for Antibodies Directed against the DNA Receptor.
￿
During the course
of experiments to verify the involvement of anti-DNA antibodies in inducing
DNA receptor dysfunction, multiple sera from patients with SLE and their
asymptomatic relatives were passed over immobilized DNA (Sepharose 4B-CNBr-
DNA). As described above, in nearly all SLE sera tested the initial neutral wash
did not induce the receptor defect, whereas a glycine eluate (pH 2.3), containing
anti-DNA antibodies did induce the receptor defect. In one serum (serum BI, a
31-yr-old woman whose mother had well-documented SLE), extensive adsorption
over Sepharose-DNA, resulted in a neutral eluate as well as a glycine eluate that
repeatedly induced the receptor defect. Furthermore, unlike the glycine eluate,
the neutral eluate abrogated [sH]DNA binding to cells that had been treated
with DNAase 1 (Table II). Ion-exchange chromatography with DEAE (Whatman
Inc.) indicated that the reactive fraction of both eluates was IgG. The inhibitory
effect of the glycine eluate in these experiments appeared to be due to the
presence of antibodies to ssDNA in serum BI. However, the neutral eluant
contained undetectable levels of antibodies to ssDNA and dsDNA or to total
histones, as determined by ELISA. Thus, serum BI appeared to contain an
antibody activity that inhibited cell-surface DNA binding, but did not contain
anti-DNA or antihistone specificities.
The ability to react with DNAase treated cells suggested that serum BI could
contain an antireceptor antibody, and this notion was explored further by
immunoblotting. Solubilized membrane proteins from PBMC were electropho-
retically separated, transferred to nitrocellulose, and then reacted with the IgG
from patient BI or IgG from a healthy donor. Antibody binding to the blotted
proteins was detected with peroxidase-conjugated goat anti-human IgG. AsTABLE II
HumoralModulation of 'H-DNA Binding ofSLE Sera Compared with Serum BI
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The serum from patient BI, an SLE serum, affinity-purified anti-DNA F(ab)2, and a
normal serum were passed over a column (5 ml) of Sepharose-DNA . The neutral
eluate and the glycine eluate were incubated with PBMC for 30 min at 37°C . After
extensive washing, the binding of ['H]DNA was assessed . An identical experiment
was performed with cells that had been treated with DNAase 1 . Each value is the
mean of triplicate experiments.
* It should be noted that serum BI contained antibodies to ssDNA but not dsDNA .
FIGURE 7 .
￿
Immunoblotting shows that the IgG from pa-
tient BI has a reactivity with the 30,000 mol wt DNA-binding
protein on cell membranes . Solubilized cell membrane pro-
teins from normal PBMC were electrophoretically separated
and transferred to nitrocellulose . Individual nitrocellulose
strips were incubated with the IgG from BI (600 tcg/ml) or
the IgG from a healthy volunteer . In one instance the strip
was preincubated with DNA (10 ug/ml) before combination
with BI's IgG . Bands of fixed IgG were visualized by means
ofaperoxidase-conjugated second antibody . The position of
IgG bands was compared with that ofaDNA-binding protein
(visualized by a probe of biotin-DNA) that migrated in a
30,000 mol wt position . (A) Biotin-DNA probe ; (B) normal
IgG; (C) BI's IgG ; (D) blocking DNA.
shown in Fig. 7, one band of staining occurred at a molecular weight of 30,000,
an identical position to that obtained with a biotin-labeled DNA probe . When
the nitrocellulose strip was first incubated with DNA (10 wg/ml) before applica-
tion of BI's IgG, or when normal IgG was substituted, no Ig binding was observed
(Fig . 7) . Thus, it appeared as if serum BI contained antibodies with specificity
for the DNA receptor . However, it was also conceivable that this technique was
measuring anti-DNA antibodies that were combined with short strands of DNA
and that binding to the receptor was mediated via this bound DNA. To test this
'H-DNA Binding assay (cpm, mean :t SD)
Serum Neutral eluate Glycine eluate
Neutral eluate Glycine eluate with DNAse/ with DNAse/
cell cell
SLE serum 3,649 ± 401 841± 68 3,324 ± 203 3,596 t 326
Serum BI* 515± 63 861± 74 535± 62 483± 54
Anti-DNA F(ab)2 3,486 ± 314 936t 83 4,426 ± 521 3,857 ± 391
Normal serum 5,034 t 441 4,135 t 279 4,286 t 445 4,326 t 426860
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possibility, the IgG fraction of BI's serum was depleted of anti-DNA antibodies
as previously described above. On gel chromatography (Sephacryl G300) the
IgG gave three peaks: one small peak at the void volume (consistent with
aggregated IgG or DNA-anti DNA complexes), a moderate peak at ^-300,000
(consistent with dimeric IgG), and a large peak at 160,000 (consistent with
monomeric IgG). Samples were taken from the 160,000 peak in positions
corresponding to the leading edge, the apex, and the trailing edge. These three
samples plus samples from the apices of the two other peaks were tested for
inhibitoryactivity for [sH]DNA binding to DNase-treated cells. In all fivesamples
a comparable degree ofinhibition was observed (data not shown). Immunoblots
using the leading edge and the trailing edge of the monomeric IgG peak gave
identical bands of IgG binding to the unprocessed serum. Thus, these results
indicate that the DNA receptor binding and inhibition did not require the
presence of anti-DNA-DNA complexes in the sera. In other experiments,
inhibitory IgG from patient BI was subjected to extensive DNAase treatment
before assay; this treatment did not decrease the ability of the patients' IgG to
inhibit binding of [sH]DNA to PBMC or its ability to bind to the 30,000 mol wt
protein by immunoblotting.
Discussion
These experiments indicate that sera from patients with SLE and MCTD
contain antibodies that interact with the cell-surface DNA or DNA receptors
found on normal PBMC. This interaction subsequently prevents the binding of
exogenous DNA to these cells. Antibodieswith atleastthreedifferentspecificities
appear to be capable of resulting in DNA receptor dysfunction, namely anti-
DNA, antihistone, and anti-DNA receptor. The conclusion that the anti-DNA
antibodies can inhibit the binding of [sH]DNA to PBMC is based upon the fact
that: (a) the F(ab)2 portion ofaffinity-purified IgG anti-DNA antibodies induced
the receptor defect; (b) two mAbs directed against DNA induced the defect; (c)
the humorally induced inhibition of [5H]DNA binding was abrogated if cells
were first subjected to DNase treatment; and (d) DNase-treated cells could be
reconstituted by incubation with exogenous DNA with a resulting restoration of
their ability to be negatively affected by anti-DNA antibodies.
It would seem likely that the interaction of the anti-DNA antibody with DNA
already present on the cell surface (2, 4-6, 16) directly affects receptor function
and the subsequent binding of[sH]DNA. Kinetic experiments indicated that the
interaction of anti-DNA antibody with the cell-surface ligand causes an acceler-
ated loss of receptor function. In previous experiments, the ty, of receptor
turnover was ^"90 min measured after the interaction with DNA. After exposure
to anti-DNA antibodies, functional receptor loss occurred within 3 min, and the
effect on receptor reexpression was prolonged. Cells rendered unable to bind
[sH]DNA by the action of anti-DNA antibodies gradually exhibited a return of
functionally active receptor over a 6-18 h time period in the absence of any
further exposure to anti-DNA antibodies. The receptor repopulation was also
completely abrogated ifthe cells were cultured in the presence ofcycloheximide
(2). These observations are consistent with the contention that after interaction
with antibodies, the DNA receptor undergoes a cycle of internalization, destruc-BENNETT ET AL.
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tion, and active regeneration (2) . The synthesis of another protein required for
cell surface expression is also possible. Previous data have indicated that ^-20%
of DNA receptors are occupied by cell-surface DNA (2), this makes it very
unlikely that the observed results are simply due to a blocking phenomenon. It
is therefore necessary to infer a linkage of cell-surface receptor molecules in such
a way that the accelerated internalization of a critical number of occupied
receptors causes a comigration of unoccupied receptors.
Unexpectedly, these experiments also demonstrated that antihistone antibodies
also affect DNA receptor function to a similar degree compared with anti-DNA
antibodies. Normal IgG, IgG depleted of anti-DNA antibodies, and unrelated
mouse mAbs of the same subclass and at the same concentration did not affect
DNA receptor function. A clue to the nature of the antihistone reactivity was
provided by reconstitution experiments of DNase-treated cells with DNA and
histones. These experiments showed a loss of antihistone-mediated inhibition if
cells were DNAse treated and reconstituted with purified DNA. A moderate but
persistent inhibition (^-28%) was noted when cells were reconstituted with
histones alone followed by antihistone antibodies; this inhibition is unexplained,
but may be due to minor amounts of DNA contamination in the histone
preparation or in the antihistone mAb. Thus, the antihistone antibodies appear
to be reactive with histones complexed to cell-surface DNA, which in turn is
bound to the DNA receptor. This explanation of the present findings would be
in accord with recent studies (16) documenting the occurrence of chromatin on
cell surfaces. The result with antihistone antibodies raises the question as to
whether any DNA-binding molecule can modulate DNA receptor expression.
We have previously described the binding of lactoferrin to cell-surface DNA (3);
in our present system, lactoferrin itself or antilactoferrin bound to the lactofer-
rin/DNA complex did not affect DNA receptor expression (our unpublished
results).
As the apparent function of the DNA receptor is to internalize and degrade
exogenous DNA (2), its paralysis by autoantibodies may be of relevance to the
elevated levels of circulating DNA that have been described in SLE (17). It is
conceivable that the production ofanti-DNA antibodies causes the elevated levels
of free DNA in SLE serum by means of the receptor dysfunction described in
this paper. Such a scenario would link increasing levels of anti-DNA antibodies
to increasing amounts of circulating DNA, and thus set in motion an accelerating
cascade of immune-complex formation.
Although the presence of anti-DNA antibodies (both to dsDNS and ssDNA)
and antihistone antibodies probably account for the modulation of DNA receptor
expression by most of the sera from patients with active SLE and kindred
disorders, it is unlikely that they account for the profound effect seen with -70%
of the sera from asymptomatic relatives of SLE patients. Many of these sera do
not have detectable levels of antinuclear antibodies although the sera from some
asymptomatic SLE relatives are documented to contain antibodies to ssDNA (18)
and antibodies to anti-DNA antibody idiotypes (19). In one serum that we have
studied in detail, extensive absorption of antibodies to ssDNA did not affect its
ability to cause receptor dysfunction. Furthermore, the adsorbed serum did not
contain antibodies to histones and was reactive with DNase-treated cells. This862
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third antibody had several of the characteristics expected of an antireceptor
antibody, including direct binding to a DNA-binding cell-surface protein by
immunoblotting. Furthermore, receptor dysfunction and binding on immuno-
blots was not dependent on the presence ofDNA-anti-DNA complexes.
Ifantibodies to the DNA receptor turn out to be a common occurrence in the
relatives ofSLE patients, it would provide an important new avenue for research
endeavors. There is increasing evidence that antibodies to ligand may be accom-
panied by an antiidiotypic response that has reactivity with the ligand's receptor
(20-22). This may also be true for anti-DNA antibodies where corresponding
antiidiotypic antibodies could possess anti-DNA receptor activity. Antibodies to
anti-DNA idiotypes have recently been described (19, 23) in the relatives of
patients with SLE as well as in inactive SLE patients. It will be of great interest
to determine whether such antibodies are also reactive with the DNA receptor.
Summary
Theability ofserafrom patients withSLE andsimilarconnectivetissue diseases
to induce dysfunction of the receptor for DNA was studied. All SLE and MCTD
sera studied resulted in marked inhibition of DNA receptor binding. Further-
more, the sera from a subgroup of patients with other rheumatic diseases and a
surprisingly high percentage ofasymptomatic relatives of SLE patients exhibited
a similar effect. The humoral factors causing this defect were shown to be of at
least three reactivities: (a) antibodies to DNA, (b) antibodies to histones, and (c)
antibodies to the DNA receptor itself. The reactivity ofanti-DNAandantihistone
antibodies is dependent upon intact cell-surface DNA, and reconstitution exper-
iments suggest that antihistone antibodies are reactive with histories complexed
to this DNA, which in turn isbound to the DNA receptor. Cells with an antibody-
induced DNA receptor defect are unable to bind DNA; the subsequent inability
to degrade DNA may have important consequences in diseases such as SLE in
which DNA-anti-DNA immune complexes are ofpathogenetic significance.
Receivedfor publication 30 March 1987 and in revisedform 18June 1987.
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